Adc Therapeutics Sa · NYSE:ADCT
Adc Therapeutics Sa — J.P. Morgan Healthcare Conference 2023
22 slides from Adc Therapeutics Sa's conference presentation, Jan 9, 2023
Slide 1: J.P. Morgan Healthcare Conference Presentation
Ameet Mallik, CEO January 11, 2023 J.P. Morgan Healthcare Conference
Slide 2: Forward-Looking Statements
2 Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a
Slide 3: About ADC Therapeutics
3 About ADC Therapeutics Strong validated technology platform in highly - potent PBD - based ADCs and a growing toolbox to develop next - generation assets Fully - integrated organization with specialized capabilities unique to ADCs Cash runway into 2Q 2025 with multiple value - driving catalysts in
Slide 4: ADCT Foundation
4 ADCT Foundation A purpose - built organization with specialized capabilities unique to ADCs 3 2 1 1) Discovery | Intelligent choice of targeting moiety + linker + payload permutation 3) CMC | High quality, consistent and scalable drug manufacturing for complex, highly potent molecules 2) Early Dev
Slide 5: Three Core Pillars to Unlock Value
5 Three Core Pillars to Unlock Value ADC: Antibody Drug Conjugate; DLBCL: Diffuse Large B - Cell Lymphoma; PBD: Pyrrolobenzodiazepine. *Have received European Commissi on approval for r/r DLBCL Short - Mid Term Mid - long Term Maximizing the ZYNLONTA Opportunity Advancing the PBD - Based Pipeline Br
Slide 6: Deep Pipeline in Hematology and Solid Tumors
6 Deep Pipeline in Hematology and Solid Tumors Anticipated milestones set forth in this chart are subject to further future adjustment based on, among other factors, the im pac t of the COVID - 19 pandemic. NTE: Non - Transplant Eligible ADCT - 212 | Targeting PSMA r/r Hodgkin Lymphoma Various Solid
Slide 7: Three Horizons to Grow ZYNLONTA to $500m-$1B in Potential Peak Sales
7 Three Horizons to Grow ZYNLONTA to $500m - $1B in Potential Peak Sales 1. Cerner Enviza's CancerMPact – Epi Database, Patient Metrics & Treatment Architecture, NH Lymphoma (2022) 2 . Clarivate's Disease Market Landscape & Forecast, Non - Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia, Epidemi
Slide 8: ZYNLONTA's Differentiated Product Profile
8 ZYNLONTA’s Differentiated Product Profile 1. Based on pivotal LOTIS - 2 trial. Full prescribing information available at www.ZYNLONTA.com , including warnings and precautions. 2. Includes patients who did not respond to first - line therapy, patients refractory to all prior lines of therapy, patie
Slide 9: ZYNLONTA: Well-Positioned to Lead in 3L/3L+ DLBCL
9 ZYNLONTA: W ell - Positioned to Lead in 3L/3L+ DLBCL 1. Symphony Health NonRetailSource and PatientSource data, 2. Internal ADC Therapeutics market research and sales data, 3. Gloria Iacoboni, Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with DLBCL Progres
Slide 10: Developing ZYNLONTA to be the Combination Agent of Choice
10 Developing ZYNLONTA to be the Combination Agent of Choice ASCT: Autologous Stem Cell Transplant; NHL: Non - Hodgkin Lymphoma; * Data cutoff for 20 patients: February 28, 2022 ▪ Phase 2 trial in combination with rituximab (guideline informing) ▪ Enrollment ongoing: 80 total patients, 40 unfit and
Slide 11: Developing the PBD-Based Pipeline
11 Developing the PBD - Based Pipeline ADCT - 212 | Targeting PSMA Metastatic Prostate Cancer Preclinical Phase 1a Phase 1b Phase 2 ADCT - 602 | Targeting CD22 Acute Lymphoblastic Leukemia ADCT - 901 | Targeting KAAG1 Various Solid Tumors ADCT - 701 | Targeting DLK1 Various Solid Tumors Expected Mil
Slide 12: ADCT-901 targeting KAAG1
12 ADCT - 901 targeting KAAG1 1. Van der Eynde. J Exp Med. 1999. Differentiation ▪ KAAG1 is an attractive ADC target with over - expression in various solid tumors 1 ▪ ADCT - 901 showed robust in vivo efficacy and improved survival in KAAG1 (+) TNBC, OC, and RCC models ▪ Combo potential with gemcita
Slide 13: ADCT-901 targeting KAAG1: potential indications
13 ADCT - 901 targeting KAAG1 KAAG1 POTENTIAL INDICATIONS ADCT - 901 Monotherapy (Ovarian) 0 5 10 15 20 25 30 35 40 45 50 0 250 500 750 1000 1250 1500 1750 Days M e a n T u m o r V o l u m e ( m m 3 ) ± S E M Vehicle ADCT-901, 1 mg/kg, qdx1 Isotype-control ADC, 1 mg/kg, qdx1 Overview KAAG1 is a rece
Slide 14: ADCT-601 targeting AXL
14 ADCT - 601 targeting AXL Differentiation ▪ AXL is thought to be overexpressed in various solid tumors ▪ In a pancreatic PDX model, ADCT - 601 showed superior activity vs. Genmab’s ADC at the same dose ▪ Sensitivity to ADCT - 601 was increased in TKI resistant EGFR mutant NSCLC cell lines, confirm
Slide 15: ADCT-601 targeting AXL: potential indications
15 ADCT - 601 targeting AXL AXL POTENTIAL INDICATIONS AXL is a recently characterized target for ADC development with significant malignant expression and efficient internalization. ADCT - 601 enables a best - in - class approach to this novel target. 1. Seer 2022 – Survival Statistics; Cancer.org –
Slide 16: ADCT-212 targeting PSMA
16 ADCT - 212 targeting PSMA 1. Hope. J Nucl Med. 2017. 2. Nguyen. Mol Cancer Res. 2016. 3. Seer 2022 – Prostate Cancer; DRG Clarivate Market Forecast Assumptio ns – Prostate Cancer 2022. Differentiation ▪ PSMA has nearly universal expression in Prostate cancer with expression highest in advanced ca
Slide 17: ADCT-602 targeting CD22
17 ADCT - 602 targeting CD22 1. Aldoss. BCJ. 2021; Cerner Enviza's CancerMPact – Epi Database, Patient Metrics & Treatment Architecture, ALL (2022) ; Seer 2022 – Acute Lymphocytic Leukemia; Physician Interviews. Differentiation ▪ ADCT - 602 is a modified version of anti - CD22 monoclonal antibody, e
Slide 18: ADCT-701 targeting DLK1
18 ADCT - 701 targeting DLK1 1. Cancer.org - Lung Cancer; Cerner Enviza's CancerMPact – Epi Database, Patient Metrics & Treatment Architecture, SCLC (2022). ACC: Adenoid Cystic Carcinoma ; NB: Neuroblastoma; PHEO: Pheochromocytoma; SCLC: Small Cell Lung Cancer Differentiation ▪ DLK1 is highly expres
Slide 19: Substantial Opportunity for ADCs in Oncology
19 Substantial Opportunity for ADCs in Oncology 1. Seer 2022 – Numbers represent the total incidence of tumors where ADCs are approved. 2. Key marketed agents limited to Enhert u, Padcev, Trodelvy, Polivy, Adcetris, Kadcyla, Blenrep, Zylonta, and Besponsa. 3. Evaluate Pharma – Sales projections refl
Slide 20: ADCT Technology Platform and Proven Track Record
20 ADCT Proven Track Record 3 clinical POC+ assets Success with PBD payload ADCT Foundation A purpose - built organization with specialized capabilities unique to ADCs 3 2 1 1) Discovery | Intelligent choice of targeting moiety + linker + payload permutation 3) CMC | High quality, consistent and sca
Slide 21: Multiple Value-Driving Catalysts Expected in 2023 and 2024
21 Multiple Value - Driving Catalysts Expected in 2023 and 2024 Advancing the Pipeline Maximizing the ZYNLONTA Opportunity ADCT - 901 (KAAG1): □ 2H 2023: Preliminary results of Phase 1 dose escalation study ADCT - 601 (AXL): □ 1H 2024: Preliminary results of Phase 1 dose escalation/ expansion study
Slide 22: Thank you
Thank you THERAPEUTICS Innovating Science. inspiring Hope.
ADC Therapeutics — J.P. Morgan Healthcare Conference 2023 on 6ix